



ITW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Meir Strahilevitz

GROUP (ART UNIT): 1644

SERIAL NO.: 10/511,818 ✓

EXAMINER: Ronald B. Schwadron

U.S. National Phase of International
Appln. No.: PCT/US03/12602

FILED: July 7, 2005

DOCKET NO.: STRM 8432W1

FOR: METHODS AND DEVICES FOR TARGETING A SITE IN A MAMMAL
AND FOR REMOVING SPECIES FROM A MAMMAL

St. Louis, Missouri
December 14, 2005

Mail Stop Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO §1.97 AND § 1.98


Sir:

The attached form PTO-1449, listing information, patents and/or literature references, is being submitted within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114. **Therefore, no fee is due.** Copies of any non-US patents or publications are submitted herewith.

The Commissioner is hereby authorized to charge any additional fees or credit overpayment under 37 CFR 1.16 and 1.17 which may be required by this paper to Deposit Account 162201. *Duplicate copies of this sheet are enclosed.*

Respectfully submitted,

Date: December 14, 2005




J. Philip Polster, #24,739
Polster, Lieder, Woodruff & Lucchesi, L.C.
Customer Number: 001688
12412 Powerscourt Drive
St. Louis, Missouri 63131-3615
Telephone: (314) 238-2400
Facsimile: (314) 238-2401

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on December 14, 2005.



J. Philip Polster



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT See Attached (Use several sheets if necessary)	ATTY. DOCKET NO.: STRM 8432W1	SERIAL NO.: 10/511,818
	APPLICANT: Meir Strahilevitz	
	Filing Date: July 7, 2005	Group: 1644

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number										Kind Code (click here)	Patent Issue Date OR US App. Pub. Date OR US Non-Published Application Filing Date	Name
	US		3	4	5	3	1	9	4		A	7-1-69	Bennett et al
	US		4	3	7	5	4	1	4		A	3-1-83	Strahilevitz
	US		4	8	1	3	9	2	4		A	3-21-89	Strahilevitz
	US		4	6	2	7	9	1	5		A	12-9-86	Kuroda
	US		5	7	5	3	2	2	7		A	5-19-98	Strahilevitz
	US		6	0	3	9	9	4	6		A	3-21-2000	Strahilevitz
	US		6	0	4	6	2	2	5		A	4-4-2000	Maddock
	US		6	2	3	1	5	3	6		A1	5-15-01	Lentz
	US		6	2	5	1	3	9	4		A1	6-26-01	Nillson
	US		6	2	6	4	6	2	3		A1	7-24-01	Strahilevitz

FOREIGN PATENT DOCUMENTS

Examiner	Document Number							Date	Country	Translation	
Initial										Yes	No
	9	6	3	7	5	1	6	11/28/1996	PCT		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Ahonen et al., Acta Oncologica (1993) Vol. 32, Nos. 7/8, pp. 723-27
		P. Aukrust et al., (8/10/99), Vol 100(6), pp. 614-20
		N. M. Bakry et al., Infec. Immunol., (1997), Vol 65 (6) pp. 2225-32
		E. A. Bayer and M. Wilchek, J. of Mol. Rec., (1990), Vol. 3(3), pp. 102-07
		B. G. Beatty et al., Cancer Res. 49, (March 15, 1989), pp. 1587-1594
		L. M. Biasucci et al., Circulation, (April 27, 1999), Vol. 99 (16) pp. 2079-84
		C. Botti et al., Int. J. Biol. Markers, (1998), Vol. 13 (2), pp. 51-69
		G. Caligiuri et al., Circulation, (September 5, 2000), Vol. 102 (10) pp. 1114-19
		J. A. Carrasquillo et al., Cancer Treatment Reports, (January 1984), Vol. 68, No. 1, pp. 317-328
		L. J. Cornfield and M. A. Sills, Eur. J. Pharmacol., (Sept 4, 1991), Vol. 202(1) pp. 113-15
		C. M. Eppler et al., J. Biol. Chem., (August 5, 1992), Vol. 267 (22), pp. 15603-12
		S. Fretier et al., J. Leukoc. Biol., (Feb. 2002), Vol. 71(2), pp. 289-94
		C. Galanos, in Encyclopedia of Immunology, I.M. Roitt and P.J. Delves eds., Academic Press, (1992), pp. 500-01



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT See Attached (Use several sheets if necessary)	ATTY. DOCKET NO.: STRM 8432W1	SERIAL NO.: 10/511,818
	APPLICANT: Meir Strahilevitz	
	Filing Date: July 7, 2005	Group: 1644

	M. Garkavij et al., Cancer Research (Suppl.), (December 1, 1995), Vol. 55, pp. 5874s – 5880s
	J. Goding et al., J. Immunological Methods, (1978), Vol. 20, pp. 241-53
	B. A. Goff et al., Br. J. Cancer, (1994), Vol. 70, pp. 474-480
	D. A. Goodwin, Antibody Immunoconjugates and Radiopharmaceuticals, (1991), Vol. 4, (4), pp. 427-434
	G. K. Hansson, Circulation, (2002) Vol. 106, pp. 1599-1601
	E. Harlow and D. Lane: "Antibodies, A Laboratory Manual", Cold Spring Harbor Laboratory (Pub. 1988), pp. 328-9, 340-1, 511, 513, 516-27, 547-52
	K. Hashimoto et al., Biochim Biophys Acta, (April 25, 1986) Vol. 856 (3), pp. 556-65
	K. E. Hellstrom and I. Hellstrom, Encyclopedia of Immunology, I.M. Roitt and P.J. Delves Eds., Academic Press (1992), pp. 1530-1531.
	R.B. Herberman; Encyclopedia of Immunology, I. M. Roitt and P.J. Delves, Eds. Academic Press (1992), pp. 1013-15
	L. M. Hinman et al., Cancer Research, (July 15, 1993), Vol 53, pp. 3336-3342
	C. Ingvar et al., Nucl. Med., (1989), Vol. 30, pp. 1224-34
	H. P. Kalofonos et al., The Journal of Nuclear Medicine, (Nov. 1990), Vol. 31, No 11, pp. 1791-1796
	J. Karvonen et al., Circulation, (2003), Vol. 108, pp. 2107-2112
	H. Koukkunen et al., Ann. Med., (2001), Vol. 33, pp. 37-47
	W-H. Lee et al., Int. J. Cardiol., (Sept-Oct 2001), Vol. 80 (2-3), pp. 135-42
	W-H. Lee et al., Cardiology, (1999), Vol. 92 (1), pp. 11-16
	M. R. Lentz, Therapeutic Apheresis, (1999), Vol. 3(1), pp. 40-49
	C. N. Lieske et al., Immunol. Lett. (Feb. 1992), Vol. 31(2), pp. 117-22
	E. Lindmark et al., JAMA (Nov. 7, 2001), Vol. 286(17), pp. 2107-13
	G. Liuzzo et al., Circulation, (Nov. 23, 1999), Vol. 100(21), pp. 2135-39
	C. Lollo et al., Nuclear Medicine Communications, (1994), Vol. 15, pp. 483-491
	M. Londei, in Encyclopedia of Immunology, I.M. Roitt and P.J. Delves Eds., Academic Press (1992), pp. 443-445
	L. K. Mahal et al., Science, (May 16, 1997), Vol. 276, pp. 1125-1128
	L. Marcus et al., American Heart Journal, (July 1985), Vol. 110 No 1, part 1, pp. 30-39
	R. Maron et al., Circulation, (2002), Vol. 106, pp. 1708-1715
	A. Mazzone et al., Atherosclerosis, (1999), Vol. 145, pp. 369-74
	D. G. McNeel et al., J. Urol. (Nov. 2000), Vol 164, No.5, pp. 1825-1829
	J. L. Middlebrook and R. B. Dorland, Microbiological Rev., (Sept. 1984), Vol. 48(3), pp. 199-221
	J. Muller et al., Circulation, (2000), Vol. 101, pp. 385-391
	A. Nagy et al., Proc. Natl. Acad. Sci USA, (1998), Vol. 95, pp. 1794-1799
	T. Nakajima et al., Circulation (Feb. 5, 2001), Vol. 105(5), pp. 570-75
	A. N. Neely et al., J. Burn Care Rehabil, (Sept.-Oct. 2002), Vol. 23, No. 5, pp. 333-40



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT See Attached (Use several sheets if necessary)	ATTY. DOCKET NO.: STRM 8432W1	SERIAL NO.: 10/511,818
	APPLICANT: Meir Strahilevitz	
	Filing Date: July 7, 2005	Group: 1644

		D. E. Newby and K. A. Fox, Br Med Bull, (2001), Vol. 59, pp. 69-87
		A. Otte et al., The Lancet, (Feb. 7, 1998), Vol. 351, pp. 417-18
		G. Paganelli et al., Int J. Cancer Suppl. 2, (1988), pp. 121-125
		V. Pasceri and E.T.H. Yeh, Circulation (1999), Vol. 100, pp. 2124-2126
		Pharmacia LKB Biotechnology, Pub. #18-1022-29, "Affinity Chromatography: Principles & Methods" (1991), 114 pages, particularly pp. 47-52
		J. Plutzky, AM. J. Cardiol., (Oct. 18, 2001), Vol. 88 (8A), pp. 10K-15K
		L. E. Rabbani, New England J. Med, (Oct. 4, 2001), Vol. 345(14), pp. 1057-59
		C. C. Raggi et al., Clin. Cancer Res., (Feb. 8, 2002), Vol. 8 (2), pp. 419-427
		S. A. Rosenberg et al., Science, (Sept. 1986), Vol. 233(4770), pp. 1318-21
		F. A. Salinas and M. G. Hanna, Jr., Eds. Contemporary Topics in Immunobiology, Vol. 15, Immune Complexes and Human Cancer, Plenum Press, (1985), pp. 1-280
		I. Schimke et al, J. Am. College of Cardiol, (2001), Vol. 38, No 1, pp. 178-183
		A.H.G.J. Schrijvers et al, Cancer Research(53),(September 15, 1993), pp. 4383-4390, Immune Complexes and Plasma Exchange in Cancer Patients
		B. Serrou and C. Rosenfeld, Eds, Elsevier/ North-Holland Biomedical Press, (1981), pp. 1-344
		E. L. Sievers et al., Blood Vol. 93(11), (June 1, 1999), pp. 3678-3684
		S. D. Singh and C. G. Booth, J. Immunol. Methods (2002), Vol. 260 (1-2) pp. 149-56
		D. A. Smith et al., Circulation, (Aug. 14, 2001), Vol. 104(7) pp. 746-9
		P. A. Sobotka et al., Free Radical Biology and Med., (1993), Vol. 14, pp. 643-647
		H. Tashiro et al., Coronary Artery Disease, (March 1997), Vol. 8 (3-4), pp. 143-147
		J. Tennvall et al., Cancer (Dec. 15, 1997), Vol. 80, No. 12 (Suppl.) pp. 2411-2418
		M.J.P.G. Van Kroonenburgh and E.K.J. Pauwels, Nucl. Med. Commun., (1988) Vol. 9, pp. 919-930
		G. Wallukat et al, New England J. Med., (Nov. 28, 2002), Vol. 347, No. 22, p. 1806
		S. Yazdani et al, American Heart J., (August 1998), Vol. 136 (2) pp. 357-61

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)